Indukern maintains sales at 456 million and invests 2% more
El conglomerado ralentiza su progresión y aumenta un 0,4% los ingresos. Leer
Grupo Indukern, a pharmaceutical holding owned by the Díaz-Varela family, reported a nearly flat revenue of 456 million euros in 2025, a 0.4% increase from 454 million euros in 2024. The company's two main businesses, Kern Pharma and Calier, saw moderate growth, with Kern Pharma's revenue rising 2.3% to 362 million euros and Calier's revenue increasing 2.2% to 93 million euros.
Indukern invested 17.7 million euros in 2025, with 10.5 million euros going to Kern Pharma and 7.2 million euros to Calier. The company also completed two acquisitions in 2025, with Calier buying Tecnofarm in Argentina and Kern Pharma acquiring Laboratorios Admira in Spain.
Written by urgent.news from Expansion ES's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
